JNJ-20788560

JNJ-20788560 is a chemical compound that is classified as a delta opioid receptor agonist. It was developed by Johnson & Johnson, a multinational corporation that specializes in pharmaceuticals, medical devices, and consumer packaged goods.

Overview

JNJ-20788560 is a synthetic compound that has been studied for its potential therapeutic applications. It is known to interact with the delta opioid receptor, a type of G protein-coupled receptor that is found in the central nervous system and peripheral tissues. This receptor is involved in a variety of physiological processes, including pain perception, mood regulation, and immune response.

Pharmacology

As a delta opioid receptor agonist, JNJ-20788560 can bind to these receptors and activate them. This can result in a variety of effects, depending on the specific location and context of the receptor activation. In preclinical studies, JNJ-20788560 has been shown to have analgesic effects, meaning it can help to relieve pain. It has also been studied for its potential effects on mood disorders, such as depression and anxiety.

Development and Research

JNJ-20788560 was developed by Johnson & Johnson, one of the largest healthcare companies in the world. The development of this compound is part of the company's broader efforts to discover and develop new treatments for a variety of health conditions.

Research on JNJ-20788560 is ongoing, and it is not currently approved for use in any country. However, the results of preclinical studies suggest that it may have potential as a treatment for conditions such as chronic pain and mood disorders.

See Also

• Opioid receptor
• Johnson & Johnson
• Pharmacology

References

‎

‎